Douglas E Levy1, Judy E Garber, Alexandra E Shields. 1. Institute for Health Policy, Massachusetts General Hospital, 50 Staniford St., Suite 901, Boston, MA 02114, USA. dlevy3@partners.org
Abstract
BACKGROUND: BRCA1/2 testing is one of the most well-established genetic tests to predict cancer risk. Guidelines are available to help clinicians determine who will benefit most from testing. OBJECTIVE: To identify women at high risk of hereditary breast and ovarian cancer and estimate their awareness of and experience with genetic testing for cancer risk. DESIGN: Analyses of the 2000 and 2005 National Health Interview Surveys. PARTICIPANTS: Women with no personal history of breast or ovarian cancer (n = 35,116). MEASUREMENTS: Risk of hereditary breast or ovarian cancer based on self-reported family history of cancer and national guidelines; self-reported awareness of genetic testing for cancer risk; discussion of genetic testing for cancer risk with a health professional; having undergone genetic testing for breast/ovarian cancer risk. RESULTS: Using guideline criteria, 0.96% of women were identified as being at high risk of hereditary breast and ovarian cancer. Among high-risk women, 54.04% were aware of genetic testing for cancer risk, 10.39% had discussed genetic testing with a health professional, and 1.41% had undergone testing for breast/ovarian cancer risk. Adjusting for survey year, high-risk women were more likely than average-risk women to have heard of genetic testing for cancer risk (RR, 1.3, 95% CI 1.2-1.4), to have discussed genetic testing with a health professional (RR 5.2, 95% CI 3.6-7.4), and to have undergone genetic testing for breast/ovarian cancer risk (RR 6.8, 95% CI 2.6-18.0). CONCLUSIONS: We find low provision of guideline-recommended advice to women for whom testing may be appropriate and of significant clinical benefit.
BACKGROUND:BRCA1/2 testing is one of the most well-established genetic tests to predict cancer risk. Guidelines are available to help clinicians determine who will benefit most from testing. OBJECTIVE: To identify women at high risk of hereditary breast and ovarian cancer and estimate their awareness of and experience with genetic testing for cancer risk. DESIGN: Analyses of the 2000 and 2005 National Health Interview Surveys. PARTICIPANTS: Women with no personal history of breast or ovarian cancer (n = 35,116). MEASUREMENTS: Risk of hereditary breast or ovarian cancer based on self-reported family history of cancer and national guidelines; self-reported awareness of genetic testing for cancer risk; discussion of genetic testing for cancer risk with a health professional; having undergone genetic testing for breast/ovarian cancer risk. RESULTS: Using guideline criteria, 0.96% of women were identified as being at high risk of hereditary breast and ovarian cancer. Among high-risk women, 54.04% were aware of genetic testing for cancer risk, 10.39% had discussed genetic testing with a health professional, and 1.41% had undergone testing for breast/ovarian cancer risk. Adjusting for survey year, high-risk women were more likely than average-risk women to have heard of genetic testing for cancer risk (RR, 1.3, 95% CI 1.2-1.4), to have discussed genetic testing with a health professional (RR 5.2, 95% CI 3.6-7.4), and to have undergone genetic testing for breast/ovarian cancer risk (RR 6.8, 95% CI 2.6-18.0). CONCLUSIONS: We find low provision of guideline-recommended advice to women for whom testing may be appropriate and of significant clinical benefit.
Authors: Basit Chaudhry; Jerome Wang; Shinyi Wu; Margaret Maglione; Walter Mojica; Elizabeth Roth; Sally C Morton; Paul G Shekelle Journal: Ann Intern Med Date: 2006-04-11 Impact factor: 25.391
Authors: Mark A Hall; Jean E McEwen; James C Barton; Ann P Walker; Edmund G Howe; Jacob A Reiss; Tara E Power; Shellie D Ellis; Diane C Tucker; Barbara W Harrison; Gordon D McLaren; Andrea Ruggiero; Elizabeth J Thomson Journal: Genet Med Date: 2005 May-Jun Impact factor: 8.822
Authors: Susan M Domchek; Tara M Friebel; Susan L Neuhausen; Theresa Wagner; Gareth Evans; Claudine Isaacs; Judy E Garber; Mary B Daly; Rosalind Eeles; Ellen Matloff; Gail E Tomlinson; Laura Van't Veer; Henry T Lynch; Olufunmilayo I Olopade; Barbara L Weber; Timothy R Rebbeck Journal: Lancet Oncol Date: 2006-03 Impact factor: 41.316
Authors: Heidi A Hamann; Jasmin A Tiro; Joanne M Sanders; Trisha V Melhado; Rachel K Funk; Melissa Y Carpentier; L Kay Bartholomew; Keith E Argenbright; Sally W Vernon Journal: J Cancer Surviv Date: 2013-08-23 Impact factor: 4.442
Authors: Celia P Kaplan; Jennifer Livaudais-Toman; Jeffrey A Tice; Karla Kerlikowske; Steven E Gregorich; Eliseo J Pérez-Stable; Rena J Pasick; Alice Chen; Jessica Quinn; Leah S Karliner Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-04-24 Impact factor: 4.254
Authors: Thomas B Silverman; Gilad J Kuperman; Alejandro Vanegas; Margaret Sin; Jill Dimond; Katherine D Crew; Rita Kukafka Journal: AMIA Annu Symp Proc Date: 2018-12-05
Authors: Phuong L Mai; Susan Thomas Vadaparampil; Nancy Breen; Timothy S McNeel; Louise Wideroff; Barry I Graubard Journal: Am J Prev Med Date: 2014-05 Impact factor: 5.043